Parathyroid Clinical Trials

64 recruitingLast updated: May 13, 2026

There are 64 actively recruiting parathyroid clinical trials across 32 countries. Studies span Not Applicable, Phase 2, Phase 3, Phase 4, Phase 1, Early Phase 1. Top locations include New York, New York, United States, Paris, France, Besançon, France. Updated daily from ClinicalTrials.gov.


Parathyroid Trials at a Glance

64 actively recruiting trials for parathyroid are listed on ClinicalTrialsFinder across 6 cities in 32 countries. The largest study group is Not Applicable with 14 trials, with the heaviest enrollment activity in New York, Paris, and Besançon. Lead sponsors running parathyroid studies include Peking Union Medical College Hospital, Shaanxi Micot Pharmaceutical Technology Co., Ltd., and Amgen.

Browse parathyroid trials by phase

Treatments under study

About Parathyroid Clinical Trials

Looking for clinical trials for Parathyroid? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Parathyroid trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Parathyroid clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 64 trials

Recruiting

Natural History Study of Parathyroid Disorders

Multiple Endocrine Neoplasia Type 1Primary HyperparathyroidismParathyroid Cancer+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)3,000 enrolled1 locationNCT04969926
Recruiting
Phase 2Phase 3

Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors

Primary HyperparathyroidismParathyroid CancerMultiple Endocrine Neoplasias+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)193 enrolled1 locationNCT07444723
Recruiting

Parathyroid Tumor Clonal Status

Primary HyperparathyroidismParathyroid TumorSecondary Hyperparathyroidism (SHPT)+1 more
Washington University School of Medicine839 enrolled1 locationNCT05997810
Recruiting

Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)

Heart FailureSarcopeniaOsteoporosis+11 more
Bettina Mittendorfer100 enrolled1 locationNCT07083557
Recruiting

Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms

Endocrine TumorsNeuroblastomaThyroid Neoplasms+2 more
National Cancer Institute (NCI)2,415 enrolled1 locationNCT01005654
Recruiting
Phase 3

A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism

HypoparathyroidismEndocrine System DiseasesParathyroid Diseases
Ascendis Pharma Bone Diseases A/S36 enrolled3 locationsNCT07081997
Recruiting

Parathyroid Assessment of Symptoms French Version

Quality of Life in Primary Hyperparathyroidism
Nantes University Hospital548 enrolled1 locationNCT06450431
Recruiting

A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)

Hypoparathyroidism
Ascendis Pharma A/S10 enrolled1 locationNCT07264634
Recruiting
Phase 2

An Cohort Study on the Safety and Efficacy of XH-02 in Treating Hypoparathyroidism

Hypoparathyroidism
Peking Union Medical College Hospital60 enrolled1 locationNCT07540286
Recruiting
Not Applicable

Radiofrequency Ablation For Recurrent Parathyroid Carcinoma

Recurrent Parathyroid Carcinoma
M.D. Anderson Cancer Center20 enrolled1 locationNCT07475780
Recruiting
Phase 2

Agnostic Therapy in Rare Solid Tumors

Cancer of Unknown PrimarySoft Tissue SarcomaCholangiocarcinoma+38 more
Instituto do Cancer do Estado de São Paulo28 enrolled8 locationsNCT06638931
Recruiting
Phase 1Phase 2

Efficacy and Safety of Subcutaneous Injection of XH-02 in the Treatment of Adult Hypoparathyroidism

Hypoparathyroidism
Peking Union Medical College Hospital15 enrolled1 locationNCT07530705
Recruiting
Phase 4

Sore Throat After Open Neck Elective Surgery

Postoperative Sore Throat, Cough, HoarsenessThyroid and Parathyroid Surgery
Saint Petersburg State University, Russia764 enrolled1 locationNCT07124650
Recruiting
Early Phase 1

Efficacy and Safety of XH02 for the Treatment of Hypoparathyroidism

Hypoparathyroidism
Peking Union Medical College Hospital6 enrolled1 locationNCT07197450
Recruiting
Phase 3

A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis

Secondary Hyperparathyroidism
Amgen24 enrolled23 locationsNCT03969329
Recruiting
Not Applicable

PRESS -PAR: Early Detection and PREvention of Symptomatic postSurgical hypoPARathyroidism After Thyroid Surgery"

Hypoparathyroidism Post-surgicalPostoperative HypoparathyroidismPostsurgical Hypoparathyroidism
Nicolas Schlegel336 enrolled1 locationNCT07491601
Recruiting
Not Applicable

Patient Navigation to Improve Surgical Access in Primary Hyperparathyroidism

Hyperparathyroidism, Primary
University of Pennsylvania76 enrolled1 locationNCT06562881
Recruiting

A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding

Hypoparathyroidism
Ascendis Pharma A/S50 enrolled1 locationNCT07345494
Recruiting
Phase 3

A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

Chronic Kidney DiseaseSecondary Hyperparathyroidism
Amgen56 enrolled43 locationsNCT03633708
Recruiting
Phase 1Phase 2

Parathyroid Allotransplant for Treatment of Hypoparathyroidism

HypoparathyroidismHypoparathyroidism Post-surgicalHypoparathyroidism Postprocedural
Peter Stock3 enrolled1 locationNCT06961071